Search Clinical Trials in the European Union

Duration
Visits
Phase
Intake methods
Cost Reimbursement
Drugs
Locations
Clinical Specialty
821-840 of 991 trials

Metastatic Colorectal Cancer: Arfolitixorin Combination Therapy

We are studying a new treatment combining arfolitixorin with standard drugs for patients with metastatic colorectal cancer. The goal is to evaluate its safety and effectiveness in improving treatment results.

Metastatic Colorectal Cancer>2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Alagille Syndrome: Long-Term Study of Livmarli

We are examining the long-term safety and effectiveness of Livmarli in patients with Alagille Syndrome. This study will help us understand how well the treatment works and its tolerability over time.

Alagille Syndrome>2 yearsMonitoring phase (IV)No PlaceboInvestigational MedicinesCost ReimbursementCardiologyHepatologyInternal Medicine

Parkinson's Disease: CVN424 Study

We are testing a new medication, CVN424, for people with Parkinson's disease to see if it helps reduce OFF time and improve overall motor function. The study also aims to evaluate its safety and effects on quality of life.

Parkinson's Disease3-6 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Chronic Rhinosinusitis with Nasal Polyps: Itepekimab Study

We are investigating whether itepekimab can help adults with chronic rhinosinusitis and nasal polyps by reducing polyp size and nasal congestion. This study will also look at its effects on overall symptoms and quality of life.

Chronic Rhinosinusitis with Nasal PolypsConfirmation phase (III)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementOtolaryngologyPulmonology

Baricitinib for Children Hospitalized with COVID-19

We are studying how the medication baricitinib works in children aged 1 to under 18 years who are hospitalized with COVID-19. This research aims to ensure the safety and proper dosing for young patients.

COVID-19≤3 monthsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteInfectious DiseasesPulmonology

Triple-Negative Breast Cancer: Sacituzumab Tirumotecan Study

We are studying a new treatment for people with previously untreated triple-negative breast cancer. This trial compares a new drug alone and with another medication against standard treatment to see which works better.

Triple Negative Breast Cancer (TNBC)>2 yearsConfirmation phase (III)Investigational MedicinesCost ReimbursementGynecology and ObstetricsOncology

Corticobasal Syndrome: Glycerol Phenylbutyrate Study

We are investigating whether glycerol phenylbutyrate can lower nerve damage markers in patients with corticobasal syndrome. This study will also look at the safety and tolerability of the treatment.

Corticobasal Syndrome6-12 monthsEfficacy phase (II)≤5 visitsStandard MedicinesCost ReimbursementInternal MedicineNeurology

ADCE-D01 for Metastatic Soft Tissue Sarcoma

We are testing a new treatment called ADCE-D01 in patients with metastatic or unresectable soft tissue sarcoma. The study aims to evaluate its safety and how well it may help fight the cancer.

Soft Tissue Sarcoma1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Psilocybin for Chemotherapy-Induced Pain Relief

We are exploring whether psilocybin can help reduce chronic pain for patients recovering from chemotherapy. The goal is to see if it improves daily activities affected by pain.

Chemotherapy-Induced Peripheral Neuropathy3-6 monthsEfficacy phase (II)≤5 visitsNo PlaceboInvestigational MedicinesCost ReimbursementNeurologyOncologyOtolaryngology

ALS and TIA: Hyperpolarized Pyruvate MRI Study

We are testing a new MRI method to see if it can help identify metabolic problems in patients with Amyotrophic Lateral Sclerosis and Transient Ischemic Attack. This may improve our understanding of these conditions.

Amyotrophic Lateral Sclerosis (ALS)Transient Ischemic Attack (TIA)>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementNeurology

HER2-Expressing Ovarian Cancer: Trastuzumab Deruxtecan with Bevacizumab

We are studying a new combination treatment for patients with HER2-expressing ovarian cancer to see if it works better than standard therapy. The trial will assess safety and how well the treatments help manage the disease.

Ovarian Cancer>2 yearsConfirmation phase (III)>20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteGynecology and ObstetricsOncology

Crohn's Disease: SAR442970 Study

We are investigating the effects of a new medication, SAR442970, on adults with moderate to severe Crohn's disease. The study aims to see if it helps improve symptoms and overall health compared to a placebo.

Crohn's Disease1-2 yearsEfficacy phase (II)>20 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteGastroenterology

Advanced Non-Small Cell Lung Cancer: MaaT033 and Cemiplimab

We are studying a new treatment combining fecal microbiotherapy with Cemiplimab for patients with advanced NSCLC who have not responded to previous therapies. This trial aims to see if this combination can improve disease control and overall health compared to standard treatments.

Advanced Non-Small Cell Lung Cancer>2 yearsEfficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementOncologyPulmonology

Citalopram for Reflux Hypersensitivity and Functional Heartburn

We are studying whether adding citalopram to existing treatments helps patients with reflux hypersensitivity or functional heartburn who still have symptoms. This trial aims to improve symptom relief for those not fully responding to current therapies.

Gastroesophageal Reflux Disease3-6 monthsMonitoring phase (IV)≤5 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteGastroenterologyPsychiatry

CIDP: Riliprubart Treatment Study

We are studying the long-term safety and effectiveness of riliprubart for individuals with chronic inflammatory demyelinating polyneuropathy. This trial will help us understand how well it works in improving disability and strength.

Chronic Inflammatory Demyelinating Polyneuropathy>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementNeurology

Budesonide for Inflammation in Functional Dyspepsia

We are studying whether Budesonide can help reduce inflammation and improve symptoms in patients with functional dyspepsia. This trial will also look at its effects on quality of life and emotional well-being.

Functional Dyspepsia3-6 monthsMonitoring phase (IV)≤5 visitsStandard MedicinesCost ReimbursementGastroenterology

Mucopolysaccharidosis Type IIIA: JR-441 Infusions

We are evaluating the safety and potential effectiveness of JR-441 infusions for patients with mucopolysaccharidosis type IIIA. This study aims to explore how well this treatment works for this rare condition.

Mucopolysaccharidosis III>2 yearsSafety phase (I)>20 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementHematologyInternal MedicinePediatrics

Cutaneous Melanoma: IMA203 Treatment Study

We are comparing a new treatment called IMA203 with the best available options for patients with advanced skin cancer. This study aims to see if IMA203 is more effective and safe for those who have already been treated.

Skin Melanoma1-2 yearsConfirmation phase (III)11-15 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Cervical Dystonia: Botulinum Toxin for Back Muscle Activity

We are studying abnormal muscle activity in the back of people with cervical dystonia. The trial will test whether botulinum toxin injections can help improve this condition and what side effects may occur.

Cervical Dystonia>2 yearsMonitoring phase (IV)Standard MedicinesCost ReimbursementInternal MedicineNeurology

ELGN-2112 for Intestinal Malabsorption in Preterm Infants

We are studying whether ELGN-2112 can help preterm infants with intestinal malabsorption achieve full feeding sooner and reduce the risk of serious complications. This trial compares the new treatment to a placebo to assess its safety and effectiveness.

Intestinal Malabsorption>2 yearsConfirmation phase (III)Standard MedicinesCost ReimbursementPartially RemoteGastroenterologyPediatrics